Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Oaknin

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 11, 2008
Human papillomavirus vaccine and cervical cancer preventionAna Oaknin, Ma Pilar Barretina
Current Opinion in Oncology|August 3, 2020
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectivesAna Oaknin, Alicia León-Castillo, Domenica Lorusso
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2019
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)Juan Francisco Grau, Lorena Farinas-Madrid, Ana Oaknin
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2021
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinomaJoyce Liu, Amit M Oza, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 21, 2022
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiationCarmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, et al.
Lancet (London, England)|January 15, 2019
Cervical cancerPaul A Cohen, Anjua Jhingran, Ana Oaknin, et al.
Critical Reviews in Oncology/Hematology|January 3, 2021
Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicineJ Alejandro Perez-Fidalgo, Francisco Grau, Lorena Fariñas, et al.
Current Opinion in Obstetrics & Gynecology|January 3, 2024
The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new eraDavid García-Illescas, Roberta Mazzeo, Carmen García-Durán, et al.
Critical Reviews in Oncology/Hematology|August 14, 2012
Treatment of metastatic cervical cancer: future directions involving targeted agentsIvan Diaz-Padilla, Bradley J Monk, Helen J Mackay, et al.
Expert Review of Anticancer Therapy|June 18, 2010
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancerJosep M Del Campo, Eva Muñoz-Couselo, Isabella Diaz de Corcuera, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 11, 2008
Human papillomavirus vaccine and cervical cancer preventionAna Oaknin, Ma Pilar Barretina
Current Opinion in Oncology|August 3, 2020
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectivesAna Oaknin, Alicia León-Castillo, Domenica Lorusso
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2019
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)Juan Francisco Grau, Lorena Farinas-Madrid, Ana Oaknin
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2021
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinomaJoyce Liu, Amit M Oza, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 21, 2022
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiationCarmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, et al.
Lancet (London, England)|January 15, 2019
Cervical cancerPaul A Cohen, Anjua Jhingran, Ana Oaknin, et al.
Critical Reviews in Oncology/Hematology|January 3, 2021
Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicineJ Alejandro Perez-Fidalgo, Francisco Grau, Lorena Fariñas, et al.
Current Opinion in Obstetrics & Gynecology|January 3, 2024
The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new eraDavid García-Illescas, Roberta Mazzeo, Carmen García-Durán, et al.
Critical Reviews in Oncology/Hematology|August 14, 2012
Treatment of metastatic cervical cancer: future directions involving targeted agentsIvan Diaz-Padilla, Bradley J Monk, Helen J Mackay, et al.
Expert Review of Anticancer Therapy|June 18, 2010
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancerJosep M Del Campo, Eva Muñoz-Couselo, Isabella Diaz de Corcuera, et al.
Pageof 18